See more : Cloopen Group Holding Limited (RAAS) Income Statement Analysis – Financial Results
Complete financial analysis of Spectrum Pharmaceuticals, Inc. (SPPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Spectrum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Zhejiang MustangBattery Co.,Ltd (605378.SS) Income Statement Analysis – Financial Results
- Sunview Group Bhd (0262.KL) Income Statement Analysis – Financial Results
- Guangdong Huatie Tongda High-speed Railway Equipment Corporation (000976.SZ) Income Statement Analysis – Financial Results
- Vita Life Sciences Limited (VLS.AX) Income Statement Analysis – Financial Results
- Lion Travel Service Co., Ltd. (2731.TW) Income Statement Analysis – Financial Results
Spectrum Pharmaceuticals, Inc. (SPPI)
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.11M | 0.00 | 0.00 | 22.62M | 109.33M | 128.37M | 146.44M | 162.56M | 186.83M | 155.85M | 267.71M | 192.96M | 74.11M | 38.03M | 28.73M | 7.67M | 5.67M | 577.00K | 258.00K | 1.00M | 2.37M | 41.11K | 1.00 | 1.00 | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 1.79M | 0.00 | 0.00 | 12.01M | 26.76M | 47.22M | 35.84M | 27.69M | 27.04M | 28.58M | 46.63M | 33.84M | 17.44M | 8.15M | 1.19M | 0.00 | 97.00K | 397.00K | 123.00K | 0.00 | 0.00 | 0.00 | -1.13M | -519.88K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 8.32M | 0.00 | 0.00 | 10.61M | 82.58M | 81.15M | 110.60M | 134.87M | 159.79M | 127.27M | 221.07M | 159.13M | 56.67M | 29.88M | 27.53M | 7.67M | 5.58M | 180.00K | 135.00K | 1.00M | 2.37M | 41.11K | 1.13M | 519.88K | 600.00K | 300.00K | 100.00K |
| Gross Profit Ratio | 82.28% | 0.00% | 0.00% | 46.91% | 75.53% | 63.22% | 75.52% | 82.97% | 85.53% | 81.66% | 82.58% | 82.46% | 76.47% | 78.57% | 95.85% | 100.00% | 98.29% | 31.20% | 52.33% | 100.00% | 100.00% | 100.00% | 112,813,400.00% | 51,987,600.00% | 600.00% | 300.00% | 100.00% |
| Research & Development | 42.20M | 87.30M | 109.38M | 79.33M | 94.96M | 65.90M | 58.94M | 50.77M | 69.66M | 46.67M | 42.54M | 27.72M | 57.30M | 21.06M | 26.68M | 33.29M | 17.87M | 12.60M | 6.95M | 3.68M | 12.73M | 20.61M | 38.77M | 20.06M | 8.50M | 4.50M | 600.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.82M | 60.41M | 60.36M | 61.37M | 90.70M | 84.27M | 87.35M | 86.51M | 97.41M | 99.32M | 91.97M | 72.55M | 48.55M | 33.61M | 15.16M | 11.58M | 13.60M | 7.50M | 5.98M | 7.62M | 4.10M | 7.58M | 5.11M | 3.47M | 3.10M | 2.30M | 700.00K |
| Other Expenses | -5.33M | -10.89M | -2.94M | -8.89M | 9.58M | 389.00K | 887.00K | -1.25M | -4.37M | -722.00K | -844.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.02M | 147.70M | 169.73M | 140.70M | 213.75M | 177.81M | 172.23M | 175.60M | 191.36M | 166.06M | 141.25M | 103.99M | 109.57M | 58.39M | 42.00M | 44.87M | 31.47M | 20.10M | 12.94M | 11.31M | 16.83M | 28.19M | 45.00M | 24.04M | 12.10M | 7.00M | 1.30M |
| Cost & Expenses | 82.81M | 147.70M | 169.73M | 140.70M | 240.51M | 225.03M | 208.07M | 203.29M | 218.40M | 194.64M | 187.88M | 137.83M | 127.01M | 66.53M | 43.20M | 44.87M | 31.57M | 20.50M | 13.06M | 11.31M | 16.83M | 28.19M | 43.87M | 23.52M | 11.60M | 6.80M | 1.30M |
| Interest Income | 968.00K | 163.00K | 1.34M | 5.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.61M | 0.00 | 0.00 | 83.00K | 0.00 | 0.00 | 776.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 998.00K | 0.00 | 0.00 | -5.00M | 340.00K | 6.80M | 9.44M | 9.07M | 8.58M | 2.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00K | 0.00 | 0.00 | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -4.36M | 286.00K | 261.00K | 3.34M | 28.10M | 27.65M | 25.95M | 38.32M | 24.29M | 20.07M | 6.74M | 5.65M | 4.51M | 3.72M | 610.00K | 255.00K | 198.00K | 682.00K | 425.00K | 346.00K | 1.33M | 2.27M | 1.13M | 519.88K | 500.00K | 200.00K | -300.00K |
| EBITDA | -77.06M | -147.70M | -169.73M | -140.70M | -93.50M | -68.62M | -34.80M | -3.66M | -11.65M | -21.58M | 86.57M | 63.69M | -52.40M | -25.45M | -10.33M | -40.08M | -26.28M | -20.52M | -12.38M | -9.81M | -9.92M | -25.68M | -42.74M | -20.78M | -11.20M | -7.20M | -1.50M |
| EBITDA Ratio | -761.91% | 0.00% | 0.00% | -622.14% | -85.52% | -53.46% | -23.76% | -2.25% | -6.23% | -13.85% | 32.34% | 33.01% | -70.70% | -66.93% | -35.94% | -522.41% | -463.18% | -3,556.15% | -4,797.29% | -980.80% | -418.13% | -62,458.85% | -4,273,686,000.00% | -2,077,988,900.00% | -11,200.00% | -7,200.00% | -1,500.00% |
| Operating Income | -72.70M | -147.70M | -169.73M | -144.03M | -131.18M | -96.66M | -61.63M | -40.73M | -31.57M | -38.79M | 79.82M | 55.13M | -52.90M | -28.51M | -19.17M | -37.20M | -25.89M | -19.92M | -12.80M | -10.47M | -17.51M | -28.15M | -43.87M | -23.52M | -11.50M | -6.70M | -1.20M |
| Operating Income Ratio | -718.78% | 0.00% | 0.00% | -636.89% | -119.98% | -75.30% | -42.08% | -25.06% | -16.90% | -24.89% | 29.82% | 28.57% | -71.37% | -74.97% | -66.74% | -484.81% | -456.43% | -3,452.69% | -4,961.24% | -1,046.80% | -738.28% | -68,469.52% | -4,387,369,500.00% | -2,352,312,900.00% | -11,500.00% | -6,700.00% | -1,200.00% |
| Total Other Income/Expenses | -5.36M | -10.73M | -1.60M | 174.20M | 11.17M | -11.37M | -9.20M | -9.65M | -11.96M | 2.15M | -844.00K | -2.91M | 4.01M | 8.74M | 3.70M | 3.14M | 581.00K | 1.28M | 2.00K | 78.00K | -126.50M | -200.69K | -8.70K | -2.22M | 200.00K | 700.00K | 300.00K |
| Income Before Tax | -78.06M | -158.43M | -171.33M | -144.59M | -120.01M | -108.03M | -70.83M | -50.38M | -43.53M | -36.64M | 78.98M | 52.22M | -48.89M | -19.77M | -22.71M | -34.06M | -25.31M | -18.64M | -12.80M | -10.62M | -20.72M | -28.35M | -43.88M | -25.75M | -11.30M | -6.00M | -900.00K |
| Income Before Tax Ratio | -771.78% | 0.00% | 0.00% | -639.37% | -109.77% | -84.15% | -48.36% | -30.99% | -23.30% | -23.51% | 29.50% | 27.06% | -65.96% | -51.99% | -79.04% | -443.90% | -446.18% | -3,231.02% | -4,960.47% | -1,061.90% | -873.80% | -68,957.67% | -4,388,239,700.00% | -2,574,649,400.00% | -11,300.00% | -6,000.00% | -900.00% |
| Income Tax Expense | 46.00K | 4.00K | -60.00K | -9.21M | 1.00K | -16.78M | -2.31M | 406.00K | 2.19M | 25.50M | -15.57M | 3.70M | -43.00K | -421.00K | 997.00K | -3.16M | -2.61M | -1.28M | -514.00K | 85.00K | 3.18M | -315.05K | 2.55M | 2.47M | 100.00K | -500.00K | 100.00K |
| Net Income | -78.10M | -158.44M | -171.27M | -135.39M | -120.01M | -91.25M | -68.51M | -50.79M | -45.72M | -62.13M | 94.55M | 48.52M | -48.84M | -19.05M | -15.47M | -34.04M | -23.28M | -18.64M | -12.29M | -10.39M | -17.63M | -27.83M | -46.43M | -25.99M | -11.60M | -6.20M | -1.00M |
| Net Income Ratio | -772.24% | 0.00% | 0.00% | -598.66% | -109.77% | -71.08% | -46.78% | -31.24% | -24.47% | -39.87% | 35.32% | 25.14% | -65.90% | -50.09% | -53.85% | -443.64% | -410.44% | -3,230.85% | -4,762.02% | -1,039.00% | -743.61% | -67,703.21% | -4,642,728,700.00% | -2,598,990,500.00% | -11,600.00% | -6,200.00% | -1,000.00% |
| EPS | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.61 | 0.94 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| EPS Diluted | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.46 | 0.86 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| Weighted Avg Shares Out | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 58.59M | 53.27M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
| Weighted Avg Shares Out (Dil) | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 64.64M | 57.96M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
NEW YORK , Jan. 26, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the...
Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff
BOSTON--( BUSINESS WIRE )--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on January 26, 2023, Spectrum's Board of Directors granted an aggregate of 20,833 inducement restricted stock units (“RSUs”) to a...
ROSEN, A Leading Law Firm, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
New York, New York--(Newsfile Corp. - January 21, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both...
Spectrum Class Action: Levi & Korsinsky Reminds Spectrum Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 3, 2023 - SPPI
New York, New York--(Newsfile Corp. - January 19, 2023) - Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.The lawsuit on behalf of Spectrum investors has been...
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action- SPPI
NEW YORK , Jan. 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the...
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action- SPPI
New York, New York--(Newsfile Corp. - January 17, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline - SPPI
New York, New York--(Newsfile Corp. - January 17, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers.
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action- SPPI
NEW YORK , Jan. 11, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action- SPPI
New York, New York--(Newsfile Corp. - January 9, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both...
Spectrum Pharmaceuticals Announces Management Changes
BOSTON--( BUSINESS WIRE )--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue...
Source: https://incomestatements.info
Category: Stock Reports